Cytokine binding by polysaccharide-antibody conjugates

Molecular Pharmaceutics

Volumn 7, Issue 5, 2010, Pages 1769-1777

  Sun, Liang Tso ^a   Buchholz, Kyle S ^a   Lotze, Michael T ^b,c,d   Washburn, Newell R ^a,d,e  

^a CARNEGIE MELLON UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c University of Pittsburgh   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

Antibody; cytokine; inflammation; polysaccharide

Indexed keywords

ANTIBODY CONJUGATE; CARBOXYMETHYLCELLULOSE; CYTOKINE; HYALURONIC ACID; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY INTERLEUKIN 1BETA CARBOXYMETHYLCELLULOSE CONJUGATE; MONOCLONAL ANTIBODY INTERLEUKIN 1BETA HYALURONIC ACID CONJUGATE; MONOCLONAL ANTIBODY TUMOR NECROSIS FACTOR ALPHA CARBOXYMETHYLCELLULOSE CONJUGATE; MONOCLONAL ANTIBODY TUMOR NECROSIS FACTOR ALPHA HYALURONIC ACID CONJUGATE; POLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL ASSAY; CYTOMETRY; DRUG CONJUGATION; DRUG PURIFICATION; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL LINE; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; INTERLEUKIN-1BETA; KINETICS; POLYSACCHARIDES; PROTEIN BINDING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957733154     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100150z     Document Type: Article

References (36)

1. Thomson, A. W.; Lotze, M. T. The Cytokine Handbook, 4th ed.; Academic Press: London, 2003; p 1536.
2. Brekke, O. H.; Sandlie, I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century Nat. Rev. Drug Discovery 2003, 2 (1) 52-62
3. Bongartz, T.; Sutton, A. J.; Sweeting, M. J.; Buchan, I.; Matteson, E. L.; Montori, V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA, J. Am. Med. Assoc. 2006, 295 (19) 2275-85
4. Veronese, F. M.; Pasut, G. PEGylation, successful approach to drug delivery Drug Discovery Today 2005, 10 (21) 1451-8
5. Kubetzko, S.; Sarkar, C. A.; Pluckthun, A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism Mol. Pharmacol. 2005, 68 (5) 1439-1454
6. Molineux, G. Pegylation: engineering improved biopharmaceuticals for oncology Pharmacotherapy 2003, 23 (8 Part 2) 3S-8S
7. Thomas, T.; Foster, G. Nanomedicines in the treatment of chronic hepatitis C - focus on pegylated interferon alpha-2a Int. J. Nanomed. 2007, 2 (1) 19-24
8. Zamboni, W. C. Pharmacokinetics of pegfilgrastim Pharmacotherapy 2003, 23 (8 Part 2) 9S-14S
9. Carter, P. H.; Zhao, Q. Clinically validated approaches to the treatment of autoimmune diseases Expert Opin. Invest. Drugs 2010, 19 (2) 195-213
10. Rozenblit, M.; Lebwohl, M. New biologics for psoriasis and psoriatic arthritis Dermatol. Ther. 2009, 22 (1) 56-60
11. Goel, N.; Stephens, S. Certolizumab pegol mAbs 2010, 2 (2) 137-147
12. Avery, R. L.; Pieramici, D. J.; Rabena, M. D.; Castellarin, A. A.; Nasir, M. A.; Giust, M. J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 2006, 113 (3) 363-372 e5
13. Streit, M.; Beleznay, Z.; Braathen, L. R. Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds Int. Wound J. 2006, 3 (3) 171-9
14. Ferrandiz, C.; Carrascosa, J. M.; Boada, A. A new era in the management of psoriasis? The biologics: facts and controversies Clin. Dermatol. 2010, 28 (1) 81-7
15. Robson, M. C.; Steed, D. L.; Franz, M. G. Wound healing: biologic features and approaches to maximize healing trajectories Curr. Probl. Surg. 2001, 38 (2) 72-140
16. Savani, R. C.; Cao, G.; Pooler, P. M.; Zaman, A.; Zhou, Z.; DeLisser, H. M. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis J. Biol. Chem. 2001, 276 (39) 36770-8
17. Bourguignon, L. Y.; Gilad, E.; Peyrollier, K.; Brightman, A.; Swanson, R. A. Hyaluronan-CD44 interaction stimulates Rac1 signaling and PKN gamma kinase activation leading to cytoskeleton function and cell migration in astrocytes J. Neurochem. 2007, 101 (4) 1002-17
18. Termeer, C.; Benedix, F.; Sleeman, J.; Fieber, C.; Voith, U.; Ahrens, T.; Miyake, K.; Freudenberg, M.; Galanos, C.; Simon, J. C. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4 J. Exp. Med. 2002, 195 (1) 99-111
19. Tesar, B. M.; Jiang, D.; Liang, J.; Palmer, S. M.; Noble, P. W.; Goldstein, D. R. The role of hyaluronan degradation products as innate alloimmune agonists Am. J. Transplant. 2006, 6 (11) 2622-35
20. Laurent, U. B.; Fraser, J. R.; Laurent, T. C. An experimental technique to study the turnover of concentrated hyaluronan in the anterior chamber of the rabbit Exp. Eye Res. 1988, 46 (1) 49-58
21. Sun, L. T.; Bencherif, S. A.; Farkas, A. M.; Gilbert, T. W.; Lotze, M. T.; Washburn, N. R. Biological activities of cytokine-neutralizing antibody-polymer conjugates Wound Repair Regen. 2010, 18 (3) 302-310
22. Jiang, D.; Liang, J.; Noble, P. W. Hyaluronan in tissue injury and repair Annu. Rev. Cell Dev. Biol. 2007, 23, 435-61
23. Steed, D. L.; Ricotta, J. J.; Prendergast, J. J.; Kaplan, R. J.; Webster, M. W.; McGill, J. B.; Schwartz, S. L. Promotion and acceleration of diabetic ulcer healing by arginine-glycine-aspartic acid (RGD) peptide matrix. RGD Study Group Diabetes Care 1995, 18 (1) 39-46
24. Falcone, S. J.; Doerfler, A. M.; Berg, R. A. Novel synthetic dermal fillers based on sodium carboxymethylcellulose: comparison with crosslinked hyaluronic acid-based dermal fillers Dermatol. Surg. 2007, 33, S136-43 discussion S143
25. Karande, P.; Mitragotri, S. Enhancement of transdermal drug delivery via synergistic action of chemicals Biochim. Biophys. Acta 2009, 1788 (11) 2362-73
26. van Osdol, W.; Fujimori, K.; Weinstein, J. N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a binding site barrier Cancer Res. 1991, 51 (18) 4776-84
27. Clauss, M. A.; Jain, R. K. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues Cancer Res. 1990, 50 (12) 3487-92
28. Israelachvili, J. Intermolecular & Surface Forces, 2nd ed.; Academic Press: London, 1992; p 450.
29. Kaminski, T.; Siebrasse, J. P.; Gieselmann, V.; Kubitscheck, U.; Kappler, J. Imaging and tracking of single hyaluronan molecules diffusing in solution Glycoconjugate J. 2008, 25 (6) 555-60
30. Klein, J.; Meyer, F. A. Tissue structure and macromolecular diffusion in umbilical cord. Immobilization of endogenous hyaluronic acid Biochim. Biophys. Acta 1983, 755 (3) 400-11
31. Homma, A.; Sato, H.; Okamachi, A.; Emura, T.; Ishizawa, T.; Kato, T.; Matsuura, T.; Sato, S.; Tamura, T.; Higuchi, Y.; Watanabe, T.; Kitamura, H.; Asanuma, K.; Yamazaki, T.; Ikemi, M.; Kitagawa, H.; Morikawa, T.; Ikeya, H.; Maeda, K.; Takahashi, K.; Nohmi, K.; Izutani, N.; Kanda, M.; Suzuki, R. Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment Bioorg. Med. Chem. 2009, 17 (13) 4647-56
32. Oh, E. J.; Park, K.; Choi, J. S.; Joo, C. K.; Hahn, S. K. Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization Biomaterials 2009, 30 (30) 6026-34
33. Kuo, J. W.; Swann, D. A.; Prestwich, G. D. Chemical modification of hyaluronic acid by carbodiimides Bioconjugate Chem. 1991, 2 (4) 232-41
34. Liu, Y.; Meng, S.; Mu, L.; Jin, G.; Zhong, W.; Kong, J. Novel renewable immunosensors based on temperature-sensitive PNIPAAm bioconjugates Biosens. Bioelectron. 2008, 24 (4) 710-5
35. Vakkila, J.; DeMarco, R. A.; Lotze, M. T. Imaging analysis of STAT1 and NF-kappaB translocation in dendritic cells at the single cell level J. Immunol. Methods 2004, 294 (1-2) 123-34
36. Moore, D. L.; Blackmore, M. G.; Hu, Y.; Kaestner, K. H.; Bixby, J. L.; Lemmon, V. P.; Goldberg, J. L. KLF family members regulate intrinsic axon regeneration ability Science 2009, 326 (5950) 298-301